UK Soft Gelatin Capsules Market Report and Forecast 2026-2034

Study Period

2021-2034

Market (2025)

USD 293.09 Million

Market (2034)

USD 495.59 Million

CAGR

6.01%

Major Markets Players

Fuji Capsule, Sirio Pharma, Captek Softgel International, EuroCaps, Soft Gel Technolog and Others

*Note: Partial List Randomly Ordered

UK Soft Gelatin Capsules Market: Insights & Analysis

The UK Soft Gelatin Capsules Market is anticipated to register a 6.01% CAGR during 2026–2034. The market size was valued at USD 293.09 million in 2025 and is projected to reach USD 495.59 million by 2034. This robust growth trajectory is underpinned by an expanding base of health-conscious consumers, a rapidly aging population, and a structurally supportive pharmaceutical manufacturing ecosystem. With 12.7 million people aged 65 and above in the UK, a demographic segment particularly receptive to easy-to-swallow softgel formulations, demand for oral dosage formats is experiencing sustained upward momentum.

Preventive healthcare trends are reinforcing nutraceutical consumption, while rising chronic disease prevalence across cardiovascular, metabolic, and neurological categories is accelerating pharmaceutical adoption of softgel drug delivery systems. England's community dispensing network, processing over 1.1 billion prescription items annually, provides an established, high-throughput distribution channel for Rx and OTC softgel products.

Key Takeaways

UK Soft Gelatin Capsules Market Dynamics

Key Market Driver: Nutraceutical Demand Fuels Softgel Adoption

Surging consumer appetite for dietary supplements, particularly omega-3 fatty acids, vitamin D, herbal extracts, and prenatal nutrition products, is the foremost demand driver for the UK soft gelatin capsules market. Industry data indicate global demand for omega-3 supplements in gelatin-based softgel formulations rose 7.4% in 2023, and the UK, as one of the world's top-five softgel-consuming nations, is a proportionate beneficiary.

The country's aging population, preventive healthcare orientation, and expanding e-commerce pharmacy channels collectively amplify softgel uptake. Furthermore, pharmaceutical manufacturers are increasingly specifying softgel formats for BCS Class II and IV poorly soluble compounds, owing to demonstrably superior bioavailability compared to conventional tablets and hard capsules, a technical advantage that continues to drive formulators toward softgel drug delivery systems.

Major Industry Challenge: Stringent Regulatory Compliance Burdens Manufacturers

One of the most significant structural challenges facing UK soft gelatin capsule manufacturers is the complexity and cost associated with meeting stringent regulatory requirements set by the Medicines and Healthcare products Regulatory Agency (MHRA) for pharmaceutical products and the Food Standards Agency (FSA) for nutraceutical supplements. Post-Brexit regulatory divergence from EU pharmacopoeia standards has introduced additional administrative overhead, requiring manufacturers to seek separate MHRA and EU certifications for cross-channel distribution.

Compliance with Good Manufacturing Practice (GMP) protocols, stability testing, dissolution validation, labeling regulations, and ingredient authorization processes substantially increases time-to-market and operational costs. Smaller manufacturers and CMOs face heightened pressures maintaining dual-compliant production, while larger players leverage established regulatory documentation frameworks as a competitive barrier against new market entrants.

Emerging Trend Shaping Outlook: Plant-Based Capsules Redefine Product Innovation

The accelerating transition toward vegetarian and vegan softgel capsule alternatives is reshaping the UK market's product innovation landscape. Non-gelatin formats based on hydroxypropyl methylcellulose (HPMC), pullulan, and starch-derived polymers are registering the highest growth rates within the broader capsule category, as UK consumers align supplement purchasing decisions with ethical, religious, and lifestyle preferences.

Global innovations, including Roquette's LYCAGEL Flex shell system and Catalent's OptiShell plant-based technology, are actively expanding the technical performance envelope of non-gelatin capsules, enabling encapsulation of complex lipid-based fills previously achievable only with gelatin matrices. As these technologies gain wider regulatory validation and commercial scale, plant-based softgels are set to capture meaningful incremental share from traditional gelatin-based formats throughout the forecast horizon.

UK Soft Gelatin Capsules Market: Segment-wise Analysis

By Product Type

The product type segmentation of the UK Soft Gelatin Capsules Market distinguishes between traditional animal-derived gelatin capsules and the emerging category of non-gelatin (vegetarian) capsules. Understanding this division is essential, as each segment serves distinct consumer profiles, formulation requirements, and regulatory pathways.

• Gelatin Soft Capsules, 78.0%
• Non-Gelatin (Vegetarian) Soft Capsules

Gelatin soft capsules command the dominant product share in the UK market, underpinned by their long-established manufacturing infrastructure, cost efficiency, and broad compatibility with pharmaceutical and nutraceutical active ingredients. Animal-derived gelatin, primarily bovine and porcine, provides excellent film-forming properties, rapid dissolution in the gastrointestinal tract, and superior stability across diverse fill formulations including oils, lipid-based solutions, and semi-solid matrices.

The proven regulatory acceptance of gelatin capsules by the MHRA, EFSA, and global pharmacopoeia bodies further entrenches their dominant position. Demand is particularly strong in pharmaceutical applications for cardiovascular drugs, oncology adjuvants, and central nervous system therapeutics where precise dose uniformity and bioavailability enhancement are critical. Although the non-gelatin segment is growing at a substantially faster rate, driven by vegan and vegetarian dietary preferences and innovation in HPMC and pullulan polymer technologies, gelatin capsules will retain a substantial majority share through 2034 due to the depth of established formulation expertise, scale economies in production, and the broad pharmaceutical customer base they serve.

By Application

Application-level segmentation reveals the dual consumer bases for UK softgel capsules, the highly regulated pharmaceutical sector and the consumer-driven nutraceutical and cosmeceutical channels. Application mix significantly influences pricing dynamics, margin structures, and regulatory complexity faced by softgel manufacturers.

• Pharmaceutical, 52.4%
• Nutraceutical
• Cosmeceutical

The pharmaceutical application segment retains the leading share of the UK soft gelatin capsules market, reflecting the critical role of softgel drug delivery in the formulation of poorly soluble active pharmaceutical ingredients. Softgel capsules are the preferred dosage form for lipid-soluble compounds, omega-3 prescription drugs, fat-soluble vitamins used therapeutically, and over-the-counter analgesics and cold-remedy products. England's community pharmacy network, which processes in excess of 1.1 billion dispensed items annually, provides a vast distribution infrastructure for Rx and OTC softgel products, reinforcing demand consistency across therapeutic categories.

Pharmaceutical-grade softgels command the highest unit values due to GMP compliance requirements, rigorous stability testing, and MHRA licensing obligations. Growth within the segment is fueled by an increasing pharmaceutical industry focus on precision dosing, bioavailability enhancement for BCS Class II and IV compounds, and the development of modified-release softgel formats, such as enteric and delayed-release capsules, that expand therapeutic applicability beyond conventional immediate-release formulations.

UK Soft Gelatin Capsules Market: Recent Developments (2025)

• Catalent Inc. entered a manufacturing agreement with Jupiter Neurosciences for JOTROL resveratrol softgel capsules supporting Parkinson's trials.
• Sirio Pharma launched XtraGummies technology in March 2025 to expand potency and sensory capability of nutraceutical softgel formats.
• Procaps Group SA advanced UK market penetration through expanded CMO partnerships, strengthening oral drug delivery softgel supply to European distributors.
• EuroCaps intensified its plant-based capsule portfolio development, responding to UK consumer demand for certified vegetarian softgel supplement formats.

UK Soft Gelatin Capsules Market: Future Outlook (2034)

The UK Soft Gelatin Capsules Market is poised to sustain a 6.01% CAGR through 2034, reaching a projected valuation of USD 495.59 million, nearly doubling in value from its 2025 base. This expansion will be driven by the convergence of an aging demographic, a deepening preventive healthcare culture, and accelerating pharmaceutical industry demand for bioavailability-enhanced oral dosage forms. Technological advancement in encapsulation, particularly AI-assisted formulation design, precision encapsulation machinery automation, and next-generation plant-based shell polymers, will progressively lower production costs and expand the addressable application spectrum for softgel formats.

Contract manufacturing organizations will play an increasingly central role, enabling pharmaceutical and nutraceutical brands to scale production without capital-intensive in-house investment. The personalized medicine trend, encompassing condition-specific supplement stacks and targeted-release pharmaceutical softgels, represents a high-growth frontier. As digital pharmacy channels and direct-to-consumer nutraceutical platforms proliferate, demand for premium, convenient softgel formats will remain structurally elevated, consolidating the UK's position as a leading European softgel capsule market through the end of the forecast period.

Why Choose This Report?

• Provides a comprehensive overview of the overall market analysis, encompassing key trends, consumer behavior analysis, and risk assessment to support strategic decision-making.
• Provides accurate, up-to-date insights into market size, segmentation, and emerging opportunities, helping to minimize risk & capitalizing on growth.
• Gives deep understanding of target audience preferences, investment habits, and communication channels for enhanced product development & marketing effectiveness.
• Delivers competitive analysis & benchmarking, uncovering the strengths & weaknesses of market competitors to guide strategies.
• Consolidate comprehensive market intelligence, reducing reasoning & streamlining research efforts.
• Facilitates customized market segmentation & risk mitigation strategies, fine-tuned to the business objectives.
• Aids in identifying both market challenges & untapped opportunities within the industry to drive long-term business growth.
• Provides valuable information based on actual customer data & search trends.